An interventional study of EVO Cognitive Remediation Game in Attention Concentration Difficulty, Depression and Anxiety, sponsored by University of Washington. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2018-08-08.
Sponsored by University of Washington · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 74 studies in Depression by University of Washington — 10 open to participants now, 13 under way, none of them phase 3. Depression · University of Washington.
Among the 74 studies in Depression by University of Washington, this one is the 46th largest by enrollment of the 71 interventional ones that give a count, is one of 6 that started in 2018, is one of 59 with no phase, and was the 36th registered.
8,582 studies on the registry are indexed under Depression; 1,723 are open to participants now.
Browse Depression studies →10 of the 74 studies in Depression by University of Washington are open now, in 3 countries. Recruiting first, the newest first:
University of Washington · Sites in Mozambique
University of Washington · Sites in United States
Ages 18+
University of Washington · Sites in Ghana
Ages 18+ · Healthy volunteers
University of Washington · Sites in United States
Ages 60+
University of Washington · Sites in United States
Ages 50+
By country, each count listing its studies:
Of the 1,089 Depression studies recruiting now, 470 (43%) set no upper age limit and 519 (48%) stop at 75 or younger; 203 take children under 18; 311 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
74 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 6 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is below the median of 81 across 7,066 interventional studies indexed under Depression.
Median enrollment 80 across the 71 interventional studies, 350 across the 3 observational. Of the 53 that completed or were terminated, 27 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Washington is the lead sponsor of 1,434 studies on the registry; 226 are open to participants now.
Of its 158 completed or terminated interventional studies of FDA-regulated products, 136 (86%) have results posted.
3 of the studies in Depression by University of Washington that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07336238University of WashingtonGroup Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies | 2026-12-01 |
| NCT05703711University of WashingtonCombining mHealth and Nurse-delivered Care to Improve the Outcomes of People With Serious Mental Illness in West Africa | 2027-05-31 |
| NCT07636434University of WashingtonMy MS Toolkit: An Internet-Based Depression Self-Management Program for Adults Living With Multiple Sclerosis | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 74 studies in Depression by University of Washington, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to determine whether a neuroscience-inspired cognitive remediation video game (EVO) that targets the cognitive control network (CCN) will improve executive functioning (EF) and resilience to psychiatric symptoms in typically developing 6th grade students, unselected for specific psychiatric symptoms. The primary goals are to 1) determine if EVO will result in improved EF and lower internalizing (e.g., mood, anxiety) and externalizing (e.g., attention deficit/hyperactivity disorder, AD/HD) psychiatric symptoms, 2) evaluate whether the benefit experienced by youth changes depending on their level of life stress (e.g., academic or social difficulties), 3) determine if EVO will promote resilience to stress. The investigators will measure EF, symptoms, and stress using self- and parent-report questionnaires. Other secondary outcomes include information on behavior in the classroom and academic performance (i.e., grades) that we will collect via school records. The investigators hypothesize that engagement with EVO 20-minutes per day, 5-days a week across 4-weeks will improve EF, lower psychiatric symptoms, improve academic/behavioral functioning at school, and decrease maladaptive responses to stress.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All children receive 4 weeks of EVO 5 days/week for 20 minutes per day in a stepped wedge design.
Other: EVO Cognitive Remediation Game
EVO (formerly called Neuroracer) is a neuroscience-inspired plasticity trainings in the form of a video driving game that uses adaptive algorithms and dual-tasking paradigms to target the CCN. Work from our group (Project:EVO) recently showed that 4 weeks of EVO training is associated with increased neural recruitment in brain regions associated with CNN, superior improvement in cognitive control performance (i.e., working memory, sustained attention) when compared to an evidence-based psychotherapy (Problem-Solving Therapy), and improved depression outcomes similar to Problem-Solving Therapy among older adults (Areán, Hallgren, Jordan, Gazzaley, Atkins, Heagerty, \& Anguera, 2016; Journal of Medical Internet Research).
Executive Function
Measuring Executive Function (e.g., attention, working memory) via parent-report of children's symptoms.
Time frame: Measured 5 times across 5 months
Behavioral Problems
Measuring difficulties with attention (i.e., attention deficit/hyperactivity disorder), oppositionality, and conduct at home and school as measured by parent-report on children's behavior.
Time frame: Measured 5 times across 5 months
Depression
depression symptoms measured with self- and parent- report
Time frame: Measured 5 times across 5 months
Anxiety
Measuring self- and parent-reported symptoms of anxiety.
Time frame: Measured 5 times across 5 months
Emotion Regulation
Measuring self-reported cognitive aspects of emotion regulation (e.g., rumination, positive reappraisal).
Time frame: Measured 5 times across 5 months
Ran from Jan 2018 to primary completion in Jun 2018, 4 months.
Of 3,471 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 4 months is below that.
Counting every sponsor, half of 3,569 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.